The Technical Analyst
Talaris Therapeutics, [TALS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Talaris Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.73% $2.72
America/New_York / 19 okt 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 116.44 mill |
| EPS: | -1.740 |
| P/E: | -1.563 |
| Earnings Date: | Nov 08, 2023 |
| SharesOutstanding: | 42.81 mill |
| Avg Daily Volume: | 0.143 mill |
| RATING 2023-10-19 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.563 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.27x |
| Company: PE -1.563 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.60 - 2.84 ( +/- 4.49%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-13 | Siegall Clay B | Buy | 20 000 | Stock Option (Right to Buy) |
| 2023-12-13 | Siegall Clay B | Buy | 0 | |
| 2023-11-17 | Kulkarni Sandeep Chidambar | Buy | 4 000 | Common Stock |
| 2023-11-17 | Thiara Parvinder | Buy | 1 000 | Common Stock |
| 2023-10-27 | Castelein Caley | Buy | 15 800 | Common Stock |
| INSIDER POWER |
|---|
| 83.75 |
| Last 89 transactions |
| Buy: 5 796 448 | Sell: 603 108 |
Forecast:
01:40 - $2.86
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.72 (-0.73% ) |
| Volume | 0.303 mill |
| Avg. Vol. | 0.143 mill |
| % of Avg. Vol | 212.34 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TALS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
TALS
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
Latest Press Releases
2023-10-19 17:37:00 - Press Release
Tourmaline Bio Announces Closing Of Merger With Talaris Therapeutics And Concurrent Private Placement Of $75 Million
Tourmaline will be focused on advancing tour006, its differentiated anti-il-6 antibody, to treat thyroid eye disease (ted), atherosclerotic cardiovascular disease (ascvd) and other diseases
2023-10-17 17:47:00 - Press Release
Talaris Therapeutics Announces Stockholder Approval Of Merger With Tourmaline Bio
Combined company to trade on nasdaq under ticker “trml” talaris announces 1-for-10 reverse stock split of common stock
2023-10-06 17:09:00 - Press Release
Talaris Therapeutics Declares Special Dividend In Connection With Proposed Merger With Tourmaline Bio
Special dividend estimated to be $1.5118 per share payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval boston, oct. 06, 2023 (globe newswire) -- talaris therapeutics, inc. (nasdaq: tals) (“talaris” or the “company”) today announced that its board of directors has declared a special dividend in connection with the previously announced merger (the “merger”) with tourmaline bio, inc. (“tourmaline”) pursuant to the agreement and plan of merger, dated june 22, 2023 (the “merger agreement”). the special dividend, which the company estimates will be $1.5118 per share of talaris common stock, will be payable in cash.
2023-10-04 08:30:00 - Press Release
New York Blood Center Enterprises Acquires Commercial-scale Cell & Gene Therapy Development And Manufacturing Facilities From Talaris Therapeutics
This acquisition expands comprehensive cell solutions, a business unit of nybce, capabilities and geographic reach as a commercial-scale cell therapy clinical development and manufacturing organization this acquisition expands comprehensive cell solutions, a business unit of nybce, capabilities and geographic reach as a commercial-scale cell therapy clinical development and manufacturing organization
2023-09-28 14:47:00 - Press Release
Talaris Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Merger Of Talaris Therapeutics, Inc. - Tals
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed merger of talaris therapeutics, inc. (nasdaqgm: tals) with tourmaline bio, inc. pursuant to which talaris shareholders will end up owning approximately 21.3% of the combined company, each on a fully diluted basis. ksf is seeking to determine whether the merger and the process that led to it are adequate, or whether th.
Latest News
2023-06-26 15:40:03 - PennyStocks
3 Hot Penny Stocks to Watch Before Next Week
Navigating the world of penny stocks can often feel like a dance, full of rhythm, calculated movements, and unexpected twists. One of the popular styles in this domain is swing trading, a strategy where investors profit from the ‘swing' or fluctuations in stock prices over a short period.
2022-10-21 12:48:23 - Zacks Investment Research
Talaris (TALS) Down on Patient Death From Renal Transplant Study
Talaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its experimental drug, FCR001, in living donor kidney transplant patients. Stock down.
2022-10-20 08:24:53 - Market Watch
Talaris Therapeutics' stock falls 21% after reporting patient death in clinical trial
Shares of Talaris Therapeutics Inc. TALS, -1.63% tumbled 21.5% in premarket trading on Thursday after the company reported one of the participants in its Phase 3 study of living donor kidney transplant recipients died. The patient had been diagnosed with a moderate form of acute graft-vs-host disease.
2022-10-04 07:00:00 - GlobeNewsWire
Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa
BOSTON and LOUISVILLE, Ky., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the 2022 Cell & Gene Meeting on the Mesa being held October 11-13, 2022 in Carlsbad, California and livestreamed globally. In addition, members from the management team will also be in attendance.
2022-09-21 07:00:00 - GlobeNewsWire
Talaris Therapeutics to Present at William Blair's Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event
BOSTON and LOUISVILLE, Ky., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at William Blair's Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event on Wednesday, September 28, 2022 at 1:00 PM ET.
2022-09-06 07:00:00 - GlobeNewsWire
Talaris Therapeutics to Participate in Two Upcoming Investor Conferences
BOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that members of its senior management team will participate in the following investor conferences:
2022-08-29 07:59:12 - Seeking Alpha
Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk
Shares of cell therapy concern Talaris Therapeutics crashed nearly 70% after GvHD outcomes in three Phase 3 trial kidney transplant patients were revealed at the end of June 2022. Even though its stock has essentially doubled off its update-induced low, it still trades at a discount to cash.
2022-06-01 07:00:00 - GlobeNewsWire
Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study
BOSTON and LOUISVILLE, Ky., June 01, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced it will host a conference call to discuss its presentations at the American Transplant Congress (ATC) and provide a data update from its ongoing Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients.
2022-05-31 07:00:00 - GlobeNewsWire
Talaris Therapeutics to Present at the Jefferies Healthcare Conference
BOSTON and LOUISVILLE, Ky., May 31, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 10:30 AM ET at the Marriott Marquis in New York, NY.
2022-05-17 16:01:00 - GlobeNewsWire
Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference
BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced today announced that Scott Requadt, Chief Executive Officer of Talaris, will be presenting virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022.